In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Directions at Tenet

Executive Summary

David Ricker, the new head of group purchasing for Tenet says that one of the first things that led him to take the new job was that, as a for-profit system, Tenet can pursue areas voluntary alliances and pure GPOs can't.

You may also be interested in...



Doubts Over China's First Alzhheimer's Drug Resurface Amid Research Miscount Allegation

Biogen/Eisai’s US filing of aducanumab for Alzheimer’s has a ripple effect in China, where a leading biomedical researcher has publicly questioned data for the country’s first approved drug for the disease, GV971.

QUOTED. 9 July 2020. Angelo De Rosa.

Boston Scientific’s VP of cardiac rhythm management business in Europe, the Middle East and Africa, Angelo De Rosa, talked to Medtech Insight about opportunities to accelerate digital health transformation during the COVID-19 crisis. See what De Rosa said about it here.

The Cost Of ‘Stacking’ Orphan Indications And A Case For Reform

Restricting orphan drug approvals could save the US billions of dollars, study from University of California’s Center for Health Policy and Economics suggests.

Topics

UsernamePublicRestriction

Register

LL1132972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel